ArticleDie Ophthalmologie2022
[Glaucoma care in Germany-results of a survey among German ophthalmologists-part 2: treatment].
Article in Die Ophthalmologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Understanding Patient Preferences and Their Impact on Adherence to Glaucoma Therapy: A Multicenter Cross-Sectional Study.Ophthalmology and therapy · 2026Article
- Evaluating surgical experience in trabeculectomy: Insights from a single-surgeon learning curve.European journal of ophthalmology · 2026Article
- Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society.Advances in therapy · 2025Article
- [Healthcare research in glaucoma].Die Ophthalmologie · 2023Article
- [Use of antiglaucomatous drugs in the urban adult population : New Insights into the prevalence of glaucoma from the Hamburg City Health Study].Die Ophthalmologie · 2023Review
- [Real-world outcomes of glaucoma surgical procedures for open-angle glaucoma].Die Ophthalmologie · 2023Review
- [How can one learn to perform a trabeculectomy? : The Mainz treatment scheme].Die Ophthalmologie · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe options for glaucoma treatment are quite diverse. The question therefore arises what is considered beneficial and feasible in daily practice. Our anonymized survey among members of the German Ophthalmological Society (DOG) and the Professional Association of Ophthalmologists in Germany (BVA) intends to explore treatment patterns and strategies in routine glaucoma care in Germany.
objectiveThe current article reflects current opinions of German ophthalmologists regarding glaucoma care, therapeutic strategies, and the role of glaucoma surgery. MATERIALS AND
methodsThe survey was conducted using an online questionnaire with 26 questions (107 items) regarding care practice for glaucoma diagnosis and treatment. Complete responses were available from 1361 participants.
resultsA total of 84.8% of responders define a target pressure regularly. A systemic therapeutic approach is followed by 44.9%. Two thirds consider side effects of eye drops to impair quality of life. Most common are conjunctival hyperemia and burning. Non-adherence to treatment is estimated to occur in 32% of patients. Approximately 5-10% of glaucoma patients are treated surgically. Among interventional treatment options, 90% consider trabeculectomy beneficial, followed by minimally invasive glaucoma surgery (MIGS) and selective laser trabeculoplasty (SLT), which are, however, the most commonly performed procedures.
conclusionThe choice of treatment should intend a long-lasting reduction of intraocular pressure and yet to be reasonable and manageable. There is a demand for more overview and structured care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.